Dravet syndrome (DS), also known as epilepsy with polymorphic seizures and polymorphic epilepsy in infancy (PMEI), is a severe and rare genetic dysfunction of the brain (epileptic encephalopathy). It usually begins in first year of life and remains throughout lifetime. Children suffering from dravet syndrome suffer from different type of seizures namely, myoclonic seizures, tonic-clonic seizures, absence seizures, atypical absence seizures, atonic seizures, focal aware or impaired awareness seizures (previously called partial seizures), and status epilepticus. Generally, combination of drugs are prescribed for the treatment of Dravet syndrome. Anticonvulsants such as stiripentol, topiramate, and Valproic acid are the most commonly used drugs for treatment of seizures and Dravet syndrome. In cases where intensity of seizures are not reduced by medication, certain devices are used to treat Dravet syndrome. Vagal nerve stimulation device is one such device, which delivers electrical impulses to the vagus nerve.
Dravet Syndrome Treatment Market Drivers